HIV/AIDS
Bavarian Nordic Enters Clinical Trials With HIV Multiantigen Vaccine
Published in AIDS Weekly, June 9th, 2008
A Phase I/II safety and immunogenicity study in 15 HIV-infected patients (CD4 counts > 350 ul/ml) has begun enrolment in the United States. The first safety data are expected by the end of 2008, while the immunogenicity data will be available during first half of 2009.
The MVA-BN(R) HIV multiantigen vaccine encodes eight genes from HIV, including Nef and thus represents a more advanced vaccine candidate compared to Bavarian Nordic's previous MVA-based HIV vaccine candidates, MVA HIV nef and MVA-BN(R) HIV polytope. In previous...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2008-06-09)
More Articles from AIDS Weekly
- Emory University
Protein that provides innate defense against HIV could lead to new treatments - Rockefeller University
Scientists image a single HIV particle being born - Antiretrovirals
Study results from E.M. Yakiwchuk and colleagues update understanding of antiretrovirals - Gilead Sciences, Inc.
Data from Pivotal Phase III Studies of Gilead's Letairis ambrisentan for Pulmonary Arterial Hypertension WHO Group 1 in Patients with WHO Functional Class II or III Symptoms Published in Circulation - HIV/AIDS
New cystic fibrosis findings from University of Munich described - HIV/AIDS
New HIV/AIDS study findings recently were reported by researchers at University of Texas - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
